| Literature DB >> 29492187 |
Sam Eriksson1,2, Hanna Borsiin1,2, Carl-Fredrik Öberg1,2, Hannes Brange1,2, Zoran Mijovic1,2, Christian Sturesson1,2.
Abstract
AIM: To investigate changes in hepatic and splenic stiffness in patients without chronic liver disease during liver resection for hepatic tumors.Entities:
Keywords: Adjuvant; Chemotherapy; Colorectal neoplasms; Elasticity imaging techniques; Hepatectomy; Liver neoplasms
Year: 2018 PMID: 29492187 PMCID: PMC5827034 DOI: 10.4240/wjgs.v10.i2.21
Source DB: PubMed Journal: World J Gastrointest Surg
Patient characteristics
| No. of patients | 4 | 16 | 15 |
| Gender (male:female) | 1:3 | 8:8 | 8:7 |
| Age (yr) | 69 (56-76) | 75 (66-79) | 66 (50-74) |
| BMI (kg/m²) | 23.5 (21.4-28.6) | 24.7 (21.8-26.8) | 26.8 (25.2-28.7) |
| Weight (kg) | 64 (53-86) | 72 (63-83) | 78 (70-90) |
| ASA physical status (1/2:3/4) | 3:1 | 10:6 | 10:5 |
| Preoperative bilirubin (µmol/L) | 5 (4-7) | 6 (5-10) | 7 (6-11) |
| Preoperative INR | 1.0 (0.9-1.0) | 1.0 (0.9-1.1) | 1.0 (1.0-1.1) |
| Diagnosis | |||
| Colorectal metastases | 3 | 13 | 11 |
| Other malignant tumors | 0 | 2 | 3 |
| Benign tumors | 1 | 1 | 1 |
| Number of hepatic tumors | 5 (1-7) | 1 (1-2) | 2 (2-6) |
| Largest hepatic tumor (mm) | 42 (17-57) | 30 (10-45) | 30 (23-51) |
| Preoperative chemotherapy | 2 | 6 | 12 |
| Oxaliplatin-based therapy | 2 | 4 | 9 |
| Liver lobe operated (right lobe:left lobe:both lobes) | - | 7:4:5 | 7:0:8 |
| Operating time (h) | 2.5 (2-3) | 3 (3-5.5) | 6 (4.5-7) |
| Operative bleeding (mL) | 125 (100-150) | 275 (150-500) | 650 (400-1100) |
| Length of hospital stay (d) | 3 (2-6) | 6 (3-9) | 6 (5-7) |
| Liver parenchyma damage | |||
| Steatosis | - | 0 | 1 |
| Steatohepatitis | - | 0 | 0 |
| SOS | - | 0 | 0 |
Data are presented as number or median (interquartile range). BMI: Body mass index; ASA: American Society of Anesthesiologists; INR: International normalized ratio; SOS: Sinusoidal obstruction syndrome.
Liver and spleen stiffness measurements for the minor and major resection groups
| No. of patients | 16 | 15 | - |
| Future liver remnant (m/s) | 1.31 (1.15-1.52) | 1.41 (1.24-1.63) | 0.318 |
| Right liver lobe preoperative (m/s) | 1.29 (1.12-1.49) | 1.38 (1.14-1.57) | 0.423 |
| Left liver lobe preoperative (m/s) | 1.35 (1.06-1.71) | 1.41 (1.29-1.63) | 0.667 |
| Spleen preoperative (m/s) | 2.76 (2.36-2.91) | 2.69 (2.33-3.11) | 0.984 |
| Liver remnant postoperative (m/s) | 1.37 (1.12-1.77) | 2.20 (1.72-2.44) | < 0.001 |
| Spleen postoperative (m/s) | 2.83 (2.44-3.18) | 2.90 (2.63-3.50) | 0.216 |
| Relative difference in liver remnant (%) | 4 (-16-24) | 42 (33-71) | 0.001 |
| Relative difference in the spleen (%) | 2 (-1-13) | 16 (7-33) | 0.047 |
Data are presented as median (interquartile range).
Figure 1Correlation between maximum postoperative bilirubin increase (A), international normalized ratio (B) and stiffness in liver remnant for patients who underwent minor (O) and major (X) resection. A: R2 = 0.154, Pearson’s r = 0.392, P = 0.032; B: R2 = 0.285, Pearson’s r = 0.534, P = 0.003. INR: International normalized ratio.